Home > Kazuhiko Nakagawa, ASCO 2019 – Phase III RELAY trial
Lung Cancer

Kazuhiko Nakagawa, ASCO 2019 – Phase III RELAY trial

Published Online: June 11th 2019

At the ASCO 2019 annual meeting, trial investigator, Kazuhiko Nakagawa discusses RELAY: A multinational, double-blind, randomized Phase III study of erlotinib in combination with ramucirumab or placebo in previously untreated patients with epidermal growth factor receptor mutation-positive (EGFRm) metastatic non-small cell lung cancer (NCT02411448).


1. What is the rationale for the use of ramucirumab plus erlotinib in metastatic EGFR-mutated non-small cell lung cancer (NSCLC)? (0:03)
2. Could you tell us a little about the RELAY study and its findings? (0:48)
3. What was the safety profile of ramucirumab plus erlotinib? (1:43)
4. Which patients are most likely to respond to this therapy? (2:49)
5. Following the success of the RELAY and REVEL studies, what will be the next steps in the clinical development of ramucirumab in NSCLC? (3:55)

Speaker disclosure: Kazuhiko Nakagawa has acted as a consultant for AstraZeneca, Eli Lilly, Boehringer Ingelheim and Roche.

Filmed at the American Society of Clinical Oncology (ASCO) 2019 Annual Meeting, Chicago, IL, USA.

Share this Video
Related Videos In Lung Cancer
  • Copied to clipboard!
    accredited arrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greyarrow-right-orangearrow-right-whitearrow-right-blueavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-whiteticktimetranscriptup-arrowwebinar